-
Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development
•
China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million) in a pre-Series C financing round led by Wuhan Hi-Tech, Hubei Science Technology Investment, and Optics Valley Financial Holding. The proceeds will be used for the clinical development of bispecific antibodies (BsAbs) and COVID-19 vaccines,…
-
Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM
•
China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Science (CAMS) regarding LXH-2201. LXH-2201 is a Category 1 drug being developed to treat cardiovascular diseases and has completed both pre-clinical and Phase…
-
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
•
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for its oral antiviral drug S-217622, developed through a joint venture with Ping An Life Insurance Company under the name Ping An-Shionogi Co., Ltd. Drug ProfileS-217622 is an oral…
-
InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
•
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its targeted protein degrader ICP-490. The drug is approved for use in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and other hematological malignancies. Drug ProfileICP-490, developed through InnoCare’s molecular glue…
-
Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
•
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA – targeted chimeric antigen receptor (CAR) T cell therapy and Novartis’ Zolgensma (OAV101) have been awarded breakthrough therapy designations (BTDs). Hrain Bio’s BCMA CAR – T cell is indicated for relapsed / refractory multiple myeloma. The…
-
Techbank Medical Closes RMB 100M Series A to Build Global Innovation Platform
•
Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series A financing round at upwards of RMB 100 million (USD 14.9 million), co – led by Puhua Capital and Hainan Qishen Venture Capital. The proceeds will go towards the establishment of its global medical device…
-
PackGene and Genemagic Partner on AAV Production and CDMO Services
•
China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd. Under the agreement, PackGene will provide Genemagic with Contract Development and Manufacturing Organization (CDMO) services for the large-scale production of adeno-associated virus (AAV). In return, Genemagic will assist PackGene in enhancing its π-beta SF9 AAV…
-
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
•
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06, an in-house developed chimeric antigen receptor (CAR)-T cell targeting B7-H3, has obtained tacit clinical trial approval for relapsed/refractory neuroblastoma. This approval signifies that the world’s first B7-H3 CAR-T therapy will enter the regulatory study phase.…
